A clinical observation of the nail pigmentation change was made on 200 patients receiving cancer chemotheray who were seen at; the Department of Internal Medicine, Seoul National University Hospital, from January through May, 1986. The results were as follows: l. Among the 200 patients, 118 cases(59%,) showed nail pigmentation changes. 2. The patterns of nail pigmentation change were as follows: Parallel transverse band(70 cases 59.3%), longitudinal pigmentated band(32 cases, 27. 1%), brown arc(25 cases, 21. 2%), Proximal black pigmentation(10 cases, 8. 5%), diffuse pigmentation(5 cases, 4.2%), parallel transverse white line(5 cases, 4.2%), half and half nail(3 cases, 2. 5%), pigmentations with transverse white band(1 case, 0. 8%). 3. Various cambinations of nail pigmentation pattern were found in 33 patients (28. 0%). 4. 11 cases of the nail dystrophy with nail pigmentation change were observed: Longitudinal ridge(7 cases), transverse groove(3 cases), wavy transverse fissure (1 case).
Drug Therapy* ; Humans ; Internal Medicine ; Pigmentation ; Seoul

A clinical observation of cutaneous complications was made on 200 patients receiving cancer chemotherapy at the Department of Internal Medicine, Seoul National University from January through May, 1986. The results were as follows: 1. Among the 200 patients, 191 case(95. 5%) showed cutaneous complications 2. The cutaneous complications included the following; hyperpigmentation(14l cases, 70. 5%), alopecia(138 cases, 69.4%), nail change(118 cases, 59.0%), mucositis(47 cases, 23.5%), dryness of the skin(40 cases, 20.0%), seborrheic dermatitis(24 cases, 12. 2%), increase of seborrheic keratosis(11 cases, 5.6%), folliculitis or acneiform eruptions(9 cases, 4,5%), melasma(6 cases, 3.0%), gynecomastia(3 cases, 1.5%), vessel hardening or dimpling(3 cases, 1.5%), radiation recall(2 cases, 1.0%), hyperhydrosis(2 cases), photosensitivity(1 case, 0.5%), tissue necrosis(1 case), facial flushing(1 case), purpura(1 case) and obesity(1 case), 3 Steps were taken to determine the chemotherapeutic agents causing these cutaneous complications, though in some cases it was difficult in determining exaetlr which chemotherapeutic agent was the cause of the observed cutaneous complication.
Drug Therapy* ; Folliculitis ; Humans ; Internal Medicine ; Seoul

No abstract available.
Blood Platelets* ; Humans* ; Membranes* ; Plasminogen*

To know the three questions about multiple primary cancers: 1) what are the characteristics of persons having multiple primary cancer? 2) Dose presence of a single primary concer after the susceptibility to multiple primary cancers? 3) Dose the location of one multiple pripary cancer influence the site of others?, we analysed 121 cases of multiple primary malignant neoplasms registered in Seoul National University Hospital during 8years from July 1978 to August 1986. Of 121 cases, double primary malignant neoplasms were 119 cases and triple were 2 cases. The incidence of multiple primary malignant neoplasms was 0.7%. The metachronous tumor(> 6 months) was found in 70 cases and the median time between the first and the second was 32 months. The most commonly associated tumors were stomach and primary liver caroinoma. Cervix and Lung cancer, Stomach and Rectal cancer, Stomach and Esophagus cancer were also commonly associated.
Cervix Uteri ; Esophageal Neoplasms ; Female ; Humans ; Incidence* ; Liver ; Lung Neoplasms ; Neoplasms, Multiple Primary ; Rectal Neoplasms ; Seoul ; Stomach

PURPOSE: Soft tissue sarcomas are uncommon primary malignancies. So studies on the effective chemotherapy for soft tissue sarcomas are limited. We started this study to evaluate the effectiveness of VIP (etoposide, ifosfamide, cisplatin) combination chemotherapy for advanced soft tissue sarcomas. MATERIALS AND METHODS: Thirty patients with recurrent or metastatic soft tissue sarcoma were treated with VIP combination chemotherapy between December 1989 and June 1996. Each patient was given etoposide 75 mg/m2, ifosfamide 1000 mg/m2, cisplatin 20 mg/m2 intravenously for five consecutive days every three weeks. Mesna (sodium-2-mercaptoethansulfonate) was given to avoid the urologic toxicity. RESULTS: Twenty-eight of 30 patients were evaluable for response, and among the 28 evaluable patients, there were 9 partial response (32%). Duration of response in 9 responders ranged from 4.1 to 16.2 months (median 8.8 months). Overall survival ranged from 1.7 to 41.5 months (median 11 months) and survival was better for patients with partial response (median survival 14.8 months vs. 9.7 months with stable disease vs. 5.1 months with progressive disease p=0.0006). Nausea and vomiting was noted in more than 90% of cycles, but was markedly severe in only 4%. Leukopenia was noted in 60% of cycles, including 11% of cycles with counts <2,000/mm3. There was no treatment related death, but we had to stop chemotherapy in 2 patients due to leukopenia (1 patient) and neurotoxicity (1 patient). CONCLUSION: Combination of etoposide, ifosfamide, and cisplatin was fairly active for advanced soft tissue sarcoma, with myelosuppresion and peripheral neuropathy being the most serious toxicities.
Cisplatin* ; Drug Therapy* ; Drug Therapy, Combination ; Etoposide* ; Humans ; Ifosfamide* ; Leukopenia ; Mesna ; Nausea ; Peripheral Nervous System Diseases ; Sarcoma* ; Vomiting

No abstract available.
Humans ; Neoplasm Metastasis* ; Stomach Neoplasms* ; Stomach* ; Technetium Tc 99m Medronate*

No abstract available.
Drug Therapy* ; Drug Therapy, Combination* ; Fluorouracil* ; Humans ; Stomach Neoplasms*

No abstract available.
Classification* ; von Willebrand Diseases* ; von Willebrand Factor*

During the period between March 1979 and August 1986, 177 patients with carcinoma of the esophagus were treated with radiotherapy in the Department of Therapeutic Radiology, SNUH. Among these, 25 patients who had incomplete treatment were excluded. So a retrospective analysis was undertaken of 152 patients who were treated by curative radiotherapy. More than 80% showed response: Complete remission (22%), partial remission (63%) and no response (15%). The overall two-year and five-year actuarial survival rate were 22.9% and 13.3% respectively. Prognostic factor was analyzed by it site, size, T stage, and tumor response. Patients with the best five-year survival rate were those who had the tumor no more than 5 cm in length (17%) or confined to the upper third of the esophagus (26.6%). Complete responders had 34.3% of 5-year actuarial survival, but no responders had 0% of survival.
Esophageal Neoplasms* ; Esophagus ; Humans ; Radiation Oncology ; Radiotherapy* ; Retrospective Studies ; Survival Rate

BACKGROUND: Bone marrow biopsies following the completion of remission-induction chemotherapy for patients of acute myelogenous leukemia (AML) whose blasts on bone marrow smear are counted less than 5%, show abnormal localization of immature precursors (the so-called ALIP defined as clusters or aggregates of small mononuclear elements with a narrow rim of light blue stained agranular cytoplasm) occasionally. The importance of ALIP in bone marrow section after antileukemic therapy is not determined yet. The purpose of this study is to elucidate the significance of ALIP on patients' remission duration and survival. METHODS: The bone marrow slides from adult AML patients who achieved complete remission (CR) after receiving first antileukemic therapy between January 1987 and April 1996 in Seoul National University Hospital were reviewed. Among them, 24 patients showed ALIP findings in their bone marrow biopsy sections and 8 patients' bone marrow were rebiopsied before next chemotherapy.We analyzed them on the histopathologic aspects. The patients who achieved CR after receiving first antileukemic therapy using Ara- C and daunorubicin were analyzed about their remission duration and survival duration according to ALIP positiveness (ALIP+ group : 16 patients, ALIP- group : 39patients. RESULTS: 1) Among eight rebiopsied bone marrow sections, six patients showed disappearance of ALIP findings spontaneously and none showed the increase of blast counts more than 5%.2) No statistically significant difference about patient characteristics between ALIP+ group and ALIP- group was shown except intervals between first antileukemic chemotherapy and biopsy of bone marrow (ALIP+ vs. ALIP-, 28 days vs. 34 days, P=0.001). The actuarial risk of relapse and CR duration were similar in both groups (P=0.44). The median duration of remission for the ALIP+ patients was 7 months and 12 months for ALIP- patients. Also the overall survival was similar in both groups (P=0.37). The median duration ofsurvival was 12 months for ALIP+ patients and 21 months for ALIP- patients. CONCLUSION: We did not find any statistically significant differences between ALIP+ group and ALIP- group for remission duration and overall survival, and observed ALIP findings in earlier bone marrow biopsies afterchemotherapy. We concluded ALIP findingmight be a indirect evidence of bone marrow regeneration, but further studies with cytogenetics or FISH method should be followed.
Adult ; Biopsy ; Bone Marrow ; Cytogenetics ; Daunorubicin ; Drug Therapy* ; Humans ; Leukemia, Myeloid, Acute* ; Recurrence ; Regeneration ; Retrospective Studies* ; Seoul